Elio review: Pixar's all-ages pleasures are in short supply in strangely half-formed animation
Elio
Director
:
Madeline Sharafian, Domee Shi, Adrian Molina
Cert
:
G
Genre
:
Animation
Starring
:
Yonas Kibreab, Zoë Saldaña, Brad Garrett, Remy Edgerly, Jameela Jamil, Shirley Henderson
Running Time
:
1 hr 38 mins
The 29th feature film from
Pixar Animation Studios
has been a troubled production, marked by repeated delays, limited marketing support and internal studio uncertainty.
Originally slated for 2024, the film was pushed to 2025 amid the company's restructuring and mass lay-offs. The original idea, based on the lonely military-base childhood of Adrian Molina, one of the directors of the Pixar film
Coco
, was reassigned to the short-film director Madeline Sharafian and Domee Shi, who made
Turning Red
.
These creative shifts tell in the finished product. The mother of the title character, once voiced by
America Ferrera
, has been replaced by
Zoë Saldaña's
aunt, a major in the US air force who specialises in space debris. The family's Latin origins are no longer part of the screenplay.
Molina's initial idea remains: Elio (Yonas Kibreab), an 11-year-old orphan, is such an oddball that the other ham-radio kids think he's weird. Since losing his parents he has been obsessed with getting abducted by aliens. Elio finally gets his wish when he's mistaken for Earth's leader, at which he's gleefully beamed up to a Day-Glo intergalactic space station, the headquarters of the Communiverse.
READ MORE
There he bonds with the equally alienated Glordon (Remy Edgerly) – picture a cuddly version of Dune's sandworms – and vexes Glordon's warlord dad, Lord Grigon (Brad Garrett).
Aesthetically, the film recalls Coco but without the elaborate world-building. Emotionally, it's pitched at the slightly hollow level of
Onward
, with plenty of synthetic lifting from Rob Simonsen's score and a lot of heavy leaning into the magic of the Voyager probe programme of the 1970s.
Elio is a half-formed thing. The basic story beats suggest that subplots and jokes have gone missing. Even the buddy comedy between Elio and Glordon is curiously marginalised. The candy-coloured character designs will please younger viewers, but the all-ages pleasures of peak Pixar are in short supply.
In cinemas from Friday, June 20th
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
7 hours ago
- Irish Times
Elio review: Pixar's all-ages pleasures are in short supply in strangely half-formed animation
Elio Director : Madeline Sharafian, Domee Shi, Adrian Molina Cert : G Genre : Animation Starring : Yonas Kibreab, Zoë Saldaña, Brad Garrett, Remy Edgerly, Jameela Jamil, Shirley Henderson Running Time : 1 hr 38 mins The 29th feature film from Pixar Animation Studios has been a troubled production, marked by repeated delays, limited marketing support and internal studio uncertainty. Originally slated for 2024, the film was pushed to 2025 amid the company's restructuring and mass lay-offs. The original idea, based on the lonely military-base childhood of Adrian Molina, one of the directors of the Pixar film Coco , was reassigned to the short-film director Madeline Sharafian and Domee Shi, who made Turning Red . These creative shifts tell in the finished product. The mother of the title character, once voiced by America Ferrera , has been replaced by Zoë Saldaña's aunt, a major in the US air force who specialises in space debris. The family's Latin origins are no longer part of the screenplay. Molina's initial idea remains: Elio (Yonas Kibreab), an 11-year-old orphan, is such an oddball that the other ham-radio kids think he's weird. Since losing his parents he has been obsessed with getting abducted by aliens. Elio finally gets his wish when he's mistaken for Earth's leader, at which he's gleefully beamed up to a Day-Glo intergalactic space station, the headquarters of the Communiverse. READ MORE There he bonds with the equally alienated Glordon (Remy Edgerly) – picture a cuddly version of Dune's sandworms – and vexes Glordon's warlord dad, Lord Grigon (Brad Garrett). Aesthetically, the film recalls Coco but without the elaborate world-building. Emotionally, it's pitched at the slightly hollow level of Onward , with plenty of synthetic lifting from Rob Simonsen's score and a lot of heavy leaning into the magic of the Voyager probe programme of the 1970s. Elio is a half-formed thing. The basic story beats suggest that subplots and jokes have gone missing. Even the buddy comedy between Elio and Glordon is curiously marginalised. The candy-coloured character designs will please younger viewers, but the all-ages pleasures of peak Pixar are in short supply. In cinemas from Friday, June 20th
Irish Times
16 hours ago
- Irish Times
Matthew Perry doctor to plead guilty to supplying ketamine to Friends star
A California doctor charged in the overdose death of Friends star Matthew Perry has agreed to plead guilty to four counts of illegal distribution of the drug ketamine, according to a court filing on Monday. Salvador Plasencia, who operated an urgent care clinic in Malibu, faces up to 40 years in prison, according to a statement from prosecutors. He is expected to enter the guilty plea in the coming weeks. Plasencia was one of five people charged in the death of Perry at age 54. READ MORE An autopsy found the actor died from acute effects of ketamine and other factors that caused him to lose consciousness and drown in his hot tub in October 2023. Ketamine is a short-acting anaesthetic with hallucinogenic properties. It is sometimes prescribed to treat depression and anxiety but also abused by recreational users. In the plea agreement, Plasencia admitted to injecting Perry with ketamine at the actor's home and in a Santa Monica parking lot in the weeks before his death, in exchange for thousands of dollars, and that it was 'not for legitimate medical purposes.' Plasencia obtained the ketamine from another doctor, Mark Chavez of San Diego. According to earlier court filings, Plasencia texted Chavez about Perry, saying: 'I wonder how much this moron will pay.' Chavez and two other defendants already have pleaded guilty in the case. None has yet been sentenced. A fifth defendant, Jasveen Sangha, whom authorities said was a drug dealer known to customers as the 'ketamine queen', has been charged with supplying the dose that killed Perry. She has pleaded not guilty and is scheduled to go on trial in August. Perry had publicly acknowledged decades of substance abuse, including during the years he starred as Chandler Bing on the hit 1990s television sitcom Friends. – Reuters
Irish Times
19 hours ago
- Irish Times
Could the end be in sight for a deadly blood cancer?
A group of 97 patients had long-standing multiple myeloma, a common blood cancer that doctors consider incurable, and faced a certain, and extremely painful, death within about a year. They had gone through a series of treatments , each of which controlled their disease for a while. But then it came back. They reached the stage where they had no more options and were facing hospice care. They all got immunotherapy, in a study that was a last-ditch effort. A third responded so well that they got what seems to be an astonishing reprieve. The immunotherapy developed by Legend Biotech, a company founded in China , seems to have made their cancer disappear. And after five years, it still has not returned in those patients – a result never before seen in this disease. READ MORE These results, in patients whose situation had seemed hopeless, has led some battle-worn oncologists to dare to say the words 'potential cure'. 'In my 30 years in oncology, we haven't talked about curing myeloma,' said Dr Norman Sharpless, a former director of the National Cancer Institute in the United States, who is now a professor of cancer policy and innovation at the University of North Carolina School of Medicine. 'This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.' The new study, reported recently at the annual conference of the American Society of Clinical Oncology and published in The Journal of Clinical Oncology, was funded by Johnson & Johnson, which has an exclusive licensing agreement with Legend Biotech. About 350 people are diagnosed with multiple myeloma each year in Ireland . It is an illness that eats away at bones, so it looks as if holes have been punched out in them, said Dr Carl June, of the University of Pennsylvania. June has seen patients who lost six inches in height. 'Right now advanced myeloma is a death sentence,' he said. There have been treatment advances that increased median survival from two years to 10 over the past two decades. But no cures. Dr Peter Voorhees, lead researcher for the newly published study, said patients usually go through treatment after treatment until, ultimately, the cancer prevails, developing resistance to every class of drug. They end up with nothing left to try. The Legend immunotherapy is a type known as CAR-T (chimeric antigen receptor T- cell therapy). It is delivered as an infusion of the patient's own white blood cells that have been removed and engineered to attack the cancer. The treatment has revolutionised prospects for patients with other types of blood cancer, such as leukaemia. Ireland's first adult CAR T-Cell centre was opened in St James's Hospital, Dublin, in 2021. Making CAR-T cells, though, is an art, with so many possible variables that it can be hard to hit on one that works. And it can have severe side effects including a high fever, trouble breathing and infections. Patients can be hospitalised for weeks after receiving it. But Legend managed to develop one that works in multiple myeloma, defying sceptics. The Chinese company – now a US company with headquarters in New Jersey – gained attention for its CAR-T eight years ago when it made extravagant claims, which were met by sniggers from researchers. [ Multiple myeloma: Patients are living longer and longer Opens in new window ] Johnson & Johnson, though, was looking for a CAR-T to call its own. So, said Mark Wildgust, an executive in the oncology section of the American drug giant, the company sent scientists and physicians to China to see if the claims were true. 'We went site by site to look at the results,' he said. The company was convinced. It initiated a collaboration with Legend and began testing the treatment in patients whose myeloma had overcome at least one standard treatment. Compared with patients who had standard treatment, those who had the immunotherapy lived longer without their disease progressing. The immunotherapy received regulatory approval in that limited setting and is sold under the brand name Carvykti. The study did not determine whether this difficult treatment saved lives. The new study took on a different challenge – helping patients at the end of the line after years of treatments. Their immune systems were worn down. They were, as oncologists said, 'heavily pretreated'. So even though CAR-T is designed to spur their immune systems to fight their cancer, it was not clear their immune systems were up to it. Oncologists say that even though most patients did not clear their cancer, having a third who did was remarkable. To see what the expected lifespan would be for these patients without the immunotherapy, Johnson & Johnson looked at data from patients in a registry who were like the ones in its study – they had failed every treatment. They lived about a year. [ Access to new cancer drugs key focus of new patient advocacy group Opens in new window ] For Anne Stovell, one of the study patients whose cancer disappeared, the result is almost too good to be true. She says she went through nine drugs to control her cancer after it was diagnosed in 2010, some of which had horrendous side effects. Each eventually failed. Taking the Legend CAR-T was difficult – she said she spent nearly three weeks in hospital. But since that treatment six years ago, she has no sign of cancer. She said it was still difficult for her to believe her myeloma is gone. A new ache – or an old one – can bring on the fear. 'There's that little seed of doubt,' she said. But in test after test, the cancer has not reappeared. – This article originally appeared in the New York Times
